Literature DB >> 2573385

Pharmacokinetics of sufentanil in neurosurgical patients undergoing hyperventilation.

A E Schwartz1, R S Matteo, E Ornstein, W L Young, M Thornhill.   

Abstract

The pharmacokinetics of sufentanil were determined in 11 hypocapnic (arterial PCO2 2.9-3.7 kPa) and seven normocapnic (arterial PCO2 5.3-6.0 kPa) neurosurgical patients. Following a single i.v. bolus of sufentanil 4 micrograms kg-1, multiple arterial samples were obtained at timed intervals and plasma concentration of sufentanil was measured by radioimmunoassay. Calculation of the pharmacokinetic parameters from the derived compartmental models demonstrated an increased total volume of distribution of sufentanil in hypocapnic patients (mean 5427 (SD 1866) ml kg-1 v. 3518 (1097) ml kg-1; P less than 0.05) in the control patients and a more prolonged elimination half-life (232 (60) min v. 143 (51) min; P less than 0.01). The increased distribution of sufentanil with hyperventilation was probably caused by an increased proportion of opioid in the nonionized state.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573385     DOI: 10.1093/bja/63.4.385

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  4 in total

Review 1.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

3.  Pharmacokinetics of sufentanil in the elderly surgical patient.

Authors:  R S Matteo; A E Schwartz; E Ornstein; W L Young; W J Chang
Journal:  Can J Anaesth       Date:  1990-11       Impact factor: 5.063

4.  Comparative absorption and distribution pharmacokinetics of intravenous and epidural sufentanil for major abdominal surgery.

Authors:  R H Taverne; T I Ionescu; S T Nuyten
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.